Tag Archives: Xgeva


MHRA Drug Safety Update June 2017

A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (vol 10, issue 11, June 2017) has been published and includes articles on:

  • Denosumab (Prolia, Xgeva▼): reports of osteonecrosis of the external auditory canal
  • Brimonidine gel (Mirvaso): risk of systemic cardiovascular effects; not to be applied to damaged skin
  • Pseudoephedrine and ephedrine: regular review of minimising risk of misuse in the UK
  • e-cigarettes and refill containers (e-liquids): report suspected side effects and safety concerns
  • Letters sent to healthcare professionals in May 2017
  • Medical Device Alerts issued in May 2017